Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Biodegradable Nanoparticles Maintain Glucose Balance in Mouse Diabetes Model

By BiotechDaily International staff writers
Posted on 30 May 2013
Image: Senior author Dr. Daniel G. Anderson (Photo courtesy of Massachusetts Institute of Technology).
Image: Senior author Dr. Daniel G. Anderson (Photo courtesy of Massachusetts Institute of Technology).
Diabetes researchers have developed an acid-degradable polymeric "nanonetwork" made up of nanoparticles loaded with insulin that can detect elevated glucose levels in the blood of diabetics and then release the hormone to return glucose levels to normal.

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) adapted nanotechnology techniques that they had developed for anticancer drug delivery to address the problem of maintaining the glucose balance in diabetes patients.

They prepared a gel-like structure containing a mixture of oppositely charged nanoparticles that by attracting each other could maintain the integrity of the gel and prevent individual nanoparticles from becoming detached. Each nanoparticle was a dextran sphere containing insulin and an enzyme capable of converting glucose to gluconic acid. The structure of the dextran sphere allowed glucose to diffuse freely, so when sugar levels in the blood were elevated, the enzyme produced large quantities of gluconic acid, lowering the pH of the local environment. The acidic environment caused the dextran spheres to disintegrate, releasing insulin into the bloodstream.

The nanoparticle gel was tested in a Type I diabetes mouse model. Results published in the May 2, 2013, online edition of the journal ACS Nano revealed that a single subcutaneous injection of the gel corrected glucose imbalance and maintained normal blood-sugar levels in the animals for an average of 10 days. As the particles were mostly composed of polysaccharides, they were biocompatible and eventually degraded in the body.

“Insulin really works, but the problem is people do not always get the right amount of it. With this system of extended release, the amount of drug secreted is proportional to the needs of the body,” said senior author Dr. Daniel Anderson, associate professor of chemical engineering at the Massachusetts Institute of Technology.

Related Links:

Massachusetts Institute of Technology



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.